Results 171 to 180 of about 12,523 (206)
Some of the next articles are maybe not open access.
Echinocandins: production and applications
Applied Microbiology and Biotechnology, 2013The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi.
Tamás, Emri +3 more
openaire +2 more sources
Echinocandin inhibition of 1,3-β-D-glucan synthase from Candida albicans
FEBS Letters, 1984 The cyclic peptide antibiotic echinocandin was found to inhibit 1,3-β-D-glucan synthase activity present in a mixed membrane fraction from Candida albicans. Addition of antibiotic reduced the Vmax of the enzyme, but the Km was unaffected.
D Kerridge
exaly +2 more sources
Update on Echinocandin Antifungals
Seminars in Respiratory and Critical Care Medicine, 2008Echinocandins are semisynthetic lipopeptides that competitively inhibit an essential cell wall component of Candida and aspergillus. They are generally inactive against other fungi. Resistance to these agents is infrequent to date. Echinocandins exhibit low oral bioavailability and are available only as parenteral formulations that are dosed once daily.
Carol A, Kauffman, Peggy L, Carver
openaire +2 more sources
Echinocandins: Are They All The Same?
Journal of Chemotherapy, 2011The discovery of echinocandins, and their development and approval, was hailed as a significant addition to our antifungal armamentarium, previously predominated by polyenes and azoles. To date, three echinocandins (anidulafungin, caspofungin, and micafungin) have been approved by the U.S.
P K, Mukherjee +4 more
openaire +2 more sources
Echinocandins for the Nursery: An Update
Current Drug Metabolism, 2013As the incidence rates of neonatal invasive fungal infection (IFI) have been increasing over the last years, research efforts have been addressed towards identifying both effective preventative strategies, and efficacious and well-tolerated antifungal drugs.
Paolo, Manzoni +7 more
openaire +2 more sources
Tetrahedron Letters, 1992
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Regina M. Black
openaire +1 more source
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Regina M. Black
openaire +1 more source
The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
Pharmacokinetics/pharmacodynamics of echinocandins
European Journal of Clinical Microbiology & Infectious Diseases, 2004The novel class of echinocandins represents a milestone in antifungal drug research that has further expanded our therapeutic options. The favorable pharmacokinetic profile of the echinocandins has been elucidated in animal and human studies. The echinocandins are targeted for once-daily dosing and are not metabolized through the cytochrome P450 enzyme
openaire +2 more sources
Caspofungin: An echinocandin antifungal agent
Clinical Therapeutics, 2002The mainstays of treatment for nosocomial fungal infections have been amphotericin B and azole derivatives. Caspofungin acetate is a new echinocandin antifungal agent with a mechanism of action that targets a structural component of the fungal cell wall.This article describes the pharmacologic properties and potential clinical usefulness of caspofungin.
Elizabeth A, Stone +2 more
openaire +2 more sources
Echinocandins: The Newest Class of Antifungals
Annals of Pharmacotherapy, 2009Objective: To review the mechanism of action, antifungal spectrum of activity, pharmacodynamics, pharmacokinetics, clinical efficacy, and safety of the echinocandins. Data Sources: A MEDLINE search (1982–May 2009) was conducted for ...
Sucher, Allana J. +2 more
openaire +2 more sources